CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2012 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: May 14, 2012 President and Chief Executive Officer EX-32.1 4 cphi10qex321033112.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: May 14, 2012 (principal financial officer and principal accounting officer) EX-32.2 5 cphi10qex322033112.htm]

By | 2016-03-03T17:44:40+00:00 May 14th, 2012|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x March 31, 2012

[FORM 10-Q (Mark One) x March 31, 2012 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: May 14, 2012 President and Chief Executive Officer EX-32.1 4 cphi10qex321033112.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: May 14, 2012 (principal financial officer and principal accounting officer) EX-32.2 5 cphi10qex322033112.htm]

By | 2016-03-03T17:46:11+00:00 May 14th, 2012|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2012 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Delaware 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:May 14, 2012 President and Chief Executive Officer cphi10qex321033112.htm 4 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:May 14, 2012 (principal financial officer and principal accounting officer) cphi10qex322033112.htm 5 EX-32.2]

By | 2016-02-07T22:00:35+00:00 May 14th, 2012|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x March 31, 2012

[FORM 10-Q (Mark One) x March 31, 2012 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Delaware 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:May 14, 2012 President and Chief Executive Officer cphi10qex321033112.htm 4 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:May 14, 2012 (principal financial officer and principal accounting officer) cphi10qex322033112.htm 5 EX-32.2]

By | 2016-02-07T22:01:08+00:00 May 14th, 2012|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 8-K: AMENDMENT AGREEMENT TO NON-QUALIFIED STOCK OPTION AGREEMENTS OF

[AMENDMENT AGREEMENT TO NON-QUALIFIED STOCK OPTION AGREEMENTS OF CHINA PHARMA HOLDINGS, INC WHEREAS, the Employment Agreement by and between the Company and the Optionee will cease its effect as of April 28, 2012; WHEREAS, the Nominating and Compensation Committee believes it is for the best interest of the Company to terminate the Subject Options on April 28, 2012 and the]

By | 2016-03-03T17:48:50+00:00 April 30th, 2012|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 8-K: (Original Filing)

[AMENDMENT AGREEMENT TO NON-QUALIFIED STOCK OPTION AGREEMENTS OF CHINA PHARMA HOLDINGS, INC WHEREAS, the Employment Agreement by and between the Company and the Optionee will cease its effect as of April 28, 2012; WHEREAS, the Nominating and Compensation Committee believes it is for the best interest of the Company to terminate the Subject Options on April 28, 2012 and the]

By | 2016-03-03T17:47:41+00:00 April 30th, 2012|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 8-K: (Original Filing)

[AMENDMENTREEMENT TO NON-QUALIFIED STOCK OPTIONREEMENTS OF CHINA PHARMAS, WHEREAS, the Employmentreement by and between thempany and the Optionee will cease its effect of April 28, 2012; WHEREAS, the Nominating andmpensationmmittee believes it is for the best interest of thempany to terminate the Subject Options on April 28, 2012 and the Optioneereed to.]

By | 2016-02-07T22:02:28+00:00 April 30th, 2012|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 8-K: AMENDMENTREEMENT TO NON-QUALIFIED STOCK OPTIONREEMENTS OF CHINA PHARMAS,

[AMENDMENTREEMENT TO NON-QUALIFIED STOCK OPTIONREEMENTS OF CHINA PHARMAS, WHEREAS, the Employmentreement by and between thempany and the Optionee will cease its effect of April 28, 2012; WHEREAS, the Nominating andmpensationmmittee believes it is for the best interest of thempany to terminate the Subject Options on April 28, 2012 and the Optioneereed to.]

By | 2016-02-07T22:03:02+00:00 April 30th, 2012|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] S-8: (Original Filing)

[] [[Cozen O’Connor Letterhead] April 27, 2012 Skystar Bio-Pharmaceutical Company 4/F, Building B, Chuangye Square, No. 48 Keji Rd Gaoxin District, Xi’an, Shaanxi Province, P.R. China Re: Registration Statement on Form S-8 In rendering this opinion, we have examined: (i) the Articles of Incorporation and By-laws of the Company, each as presently in effect; (ii) resolutions of the Company’s Board of] [Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in this Registration Statement on Form S-8 of Skystar Bio-Pharmaceutical Company of our report dated March 30, 2012 relating to the consolidated financial statements appearing in the Annual Report on Form 10-K of Skystar Bio-Pharmaceutical Company for the year ended December 31, 2011. Sherman Oaks, California]

By | 2016-03-01T04:44:36+00:00 April 27th, 2012|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] S-8:

[] [[Cozen O’Connor Letterhead] April 27, 2012 Skystar Bio-Pharmaceutical Company 4/F, Building B, Chuangye Square, No. 48 Keji Rd Gaoxin District, Xi’an, Shaanxi Province, P.R. China Re: Registration Statement on Form S-8 In rendering this opinion, we have examined: (i) the Articles of Incorporation and By-laws of the Company, each as presently in effect; (ii) resolutions of the Company’s Board of] [Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in this Registration Statement on Form S-8 of Skystar Bio-Pharmaceutical Company of our report dated March 30, 2012 relating to the consolidated financial statements appearing in the Annual Report on Form 10-K of Skystar Bio-Pharmaceutical Company for the year ended December 31, 2011. Sherman Oaks, California]

By | 2016-03-01T04:45:08+00:00 April 27th, 2012|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar